Why the study?
This review summarizes the recent literature on the renoprotective mechanisms of dexmedetomidine.
Does dexmedetomidine provide renoprotective effects in surgical settings?
Does dexmedetomidine provide renoprotective effects in surgical settings?
Dexmedetomidine shows promise in acute kidney injury prevention and management across diverse surgical contexts through multiple renoprotective mechanisms.
Answers are grounded in this paper and cite their sources.
Dex renoprotection mechanisms are mechanistically promising; leaves open prospective trials to confirm clinical kidney outcomes in surgery.
Purpose of Review This review summarizes the recent literature on the renoprotective mechanisms of Dexmedetomidine (Dex). Recent Findings Dex, an α2-adrenergic agonist with sedative, analgesic, and anti-inflammatory properties, has demonstrated efficacy in various surgical settings. The renoprotective mechanisms of Dex includes suppression of reactive oxygen species (ROS) production, apoptosis, and inflammatory cytokines. Dex also regulates pathways such as TLR4/MyD88/ERK, α2-adrenoreceptor/AMPK/mTOR, and PI3K-Akt. Additionally, Dex’s inhibition of KDM5A, and regulation of BMP-7 and HDAC2/HDAC5, attenuates renal damage. It inhibits ferroptosis-mediated renal injury, modulates vasoreactivity to maintain hemodynamics, and improves renal blood flow post-surgery. Summary The renoprotective mechanisms of Dex involve inhibition of oxidative stress and apoptosis, modulation of inflammatory cytokine responses, and vasoreactivity. Dex shows promise in AKI prevention and management across diverse surgical contexts, highlighting its value in perioperative care.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: